The research laboratory of Mark R. Kelley, MS, PhD focuses on translational research in DNA damage and repair, specifically, to determine how those activities can be exploited therapeutically to treat cancers and protect normal cells from oxidative and DNA base damage. We have focused specifically on the enzyme apurinic/apyrimidinic endonuclease 1/ Redox effector factor-1 (APE1/Ref-1)—mechanistically as well as a therapeutic target in cancers and other diseases that manifest cancer-like properties. APE1/Ref-1 is unique to the Base Excision Repair Pathway (BER), with dual repair and redox signaling functions that are crucial to cellular viability. We have concentrated on teasing apart these functions and in the process, we have discovered and have been developing redox-specific inhibitors of Ref-1.This original work was the impetus for becoming Chief Scientific Founder and Officer of Apexian Pharmaceutical targeting Ref-1 to produce new therapeutics for some of the deadliest and hardest-to-treat cancers. Apexian recently completed a phase I clinical trial using oral APX3330 in solid tumor patients (NCT03375086). Phase II trials are being developed in cancer and other indications including ocular diseases. A phase IIb trial using APX3330 in diabetic retinopathy (DR) has recently completed (NCT04692688) using a drug we developed and licensed to Ocuphire Pharma. Our lab is dedicated to fast-tracking collaboration and translational research to find more effective cancer treatments as well as treatments for other diseases related to APE1/Ref-1. We are also committed to Diversity, Equity, and Inclusion in our lab and this institution and strongly support women in science as well as mentor scientists from many different backgrounds. All of the discoveries during my career have culminated in 19 patents and over 196 articles in peer reviewed journals as well as 36 review articles/book chapters, attesting to my contributions to the field of DNA repair, redox signaling and drug development. I am a recent AAAS Science Fellow (2022). Current h index is 76.